HRP20180468T1 - Novi derivat analoga inzulina - Google Patents

Novi derivat analoga inzulina Download PDF

Info

Publication number
HRP20180468T1
HRP20180468T1 HRP20180468TT HRP20180468T HRP20180468T1 HR P20180468 T1 HRP20180468 T1 HR P20180468T1 HR P20180468T T HRP20180468T T HR P20180468TT HR P20180468 T HRP20180468 T HR P20180468T HR P20180468 T1 HRP20180468 T1 HR P20180468T1
Authority
HR
Croatia
Prior art keywords
compound
administered
compound according
diabetes
treatment
Prior art date
Application number
HRP20180468TT
Other languages
English (en)
Inventor
Peter Madsen
Tina Møller TAGMOSE
Helle Naver
Thomas Børglum KJELDSEN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of HRP20180468T1 publication Critical patent/HRP20180468T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Claims (11)

1. A14E, B16E, B25H, B29K(N(eps)-Ejkozandioil-gGlu-2xOEG), desB30 humani inzulin.
2. Spoj prema patentnom zahtjevu 1, za uporabu kao lijek.
3. Spoj prema patentnom zahtjevu 1, za uporabu kao lijek za liječenje dijabetesa.
4. Spoj prema patentnom zahtjevu 1, za uporabu u tretmanu dijabetesa, naznačeno time da je spoj primijenjen na istog pacijenta svaki drugi dan, ili rjeđe, i, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
5. Spoj prema patentnom zahtjevu 1, za uporabu u liječenju dijabetesa, naznačeno time da je spoj primijenjen dva puta tjedno, ili rjeđe, i, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
6. Spoj prema patentnom zahtjevu 1, za uporabu u liječenju dijabetesa, naznačeno time da je spoj primjenjen jednom tjedno, ili rjeđe, i, u prosjeku, tijekom vremenskog perioda od najmanje 1 mjeseca, 6 mjeseci ili 1 godine, navedeni spoj nije primjenjen češće na istog pacijenta.
7. Vodena otopina koja sadrži spoj prema patentnom zahtjevu 1.
8. Vodena otopina prema patentnom zahtjevu 7, koja sadrži najmanje 5 iona cinka po heksameru inzulina.
9. Vodena otopina prema bilo kojem od patentnih zahtjeva 7-8, gdje je pH u opsegu od 7 do 8.
10. Farmaceutska kompozicija koja sadrži spoj prema patentnom zahtjevu 1, i jedan ili više ekscipijensa.
11. Farmaceutska kompozicija prema patentnom zahtjevu 10, koja sadrži najmanje 4.5 iona cinka po heksameru inzulina.
HRP20180468TT 2013-10-07 2018-03-20 Novi derivat analoga inzulina HRP20180468T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187626 2013-10-07
PCT/EP2014/071236 WO2015052088A1 (en) 2013-10-07 2014-10-03 Novel derivative of an insulin analogue
EP14780512.1A EP3055325B1 (en) 2013-10-07 2014-10-03 Novel derivative of an insulin analogue

Publications (1)

Publication Number Publication Date
HRP20180468T1 true HRP20180468T1 (hr) 2018-05-04

Family

ID=49301382

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180468TT HRP20180468T1 (hr) 2013-10-07 2018-03-20 Novi derivat analoga inzulina

Country Status (21)

Country Link
US (1) US9896496B2 (hr)
EP (1) EP3055325B1 (hr)
JP (1) JP6499184B2 (hr)
KR (1) KR20160065126A (hr)
CN (1) CN105636979B (hr)
AU (1) AU2014333979B2 (hr)
BR (1) BR112016007166A2 (hr)
CA (1) CA2926701A1 (hr)
DK (1) DK3055325T3 (hr)
ES (1) ES2676065T3 (hr)
HR (1) HRP20180468T1 (hr)
HU (1) HUE036702T2 (hr)
IL (1) IL244507B (hr)
MX (1) MX366636B (hr)
PL (1) PL3055325T3 (hr)
PT (1) PT3055325T (hr)
RS (1) RS57004B1 (hr)
RU (1) RU2673185C2 (hr)
SA (1) SA516370893B1 (hr)
SI (1) SI3055325T1 (hr)
WO (1) WO2015052088A1 (hr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018083335A1 (en) 2016-11-07 2018-05-11 Novo Nordisk A/S Dchbs-active esters of peg compounds and their use
RU2758367C2 (ru) * 2016-12-16 2021-10-28 Ново Нордиск А/С Фармацевтические композиции, содержащие инсулин
KR102612576B1 (ko) 2017-09-29 2023-12-12 한미약품 주식회사 링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
CN111909255A (zh) * 2019-05-10 2020-11-10 宁波鲲鹏生物科技有限公司 胰岛素衍生物及其制备方法
JP2023534531A (ja) 2020-07-24 2023-08-09 チアンスー ジェンサイエンス インコーポレイテッド インスリン－Ｆｃ融合タンパク質及びその応用
KR20240013778A (ko) * 2021-05-24 2024-01-30 선샤인 레이크 파르마 컴퍼니 리미티드 신규한 아실화된 인슐린 유사체

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832685A (en) 1952-05-24 1958-04-29 Crest Foods Co Inc Solubilization of milk proteins
US3528960A (en) 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3719655A (en) 1969-12-05 1973-03-06 Lilly Co Eli Process for the crystallization of the ammonium and alkali metal salts in insulin
US3869437A (en) 1970-05-08 1975-03-04 Nat Res Dev Mono-, di, and N{HD A1{B , N{HU B1{B , N{HU B29{B -tri-acylated insulin
US3950517A (en) 1970-05-08 1976-04-13 National Research Development Corporation Insulin derivatives
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4033941A (en) 1975-12-17 1977-07-05 Eli Lilly And Company Process for purifying glucagon
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
ATE93238T1 (de) 1988-07-20 1993-09-15 Novo Nordisk As Menschliche insulinanalage und zubereitungen daraus.
US5225323A (en) 1988-11-21 1993-07-06 Baylor College Of Medicine Human high-affinity neurotransmitter uptake system
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
US5716927A (en) 1988-12-23 1998-02-10 Novo Nordisk A/S Insulin analogs having a modified B-chain
DE3844211A1 (de) 1988-12-29 1990-07-05 Hoechst Ag Neue insulinderivate, verfahren zu deren herstellung, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE69018461T2 (de) 1989-04-20 1995-08-03 Sinai School Medicine Hepatospezifische insulin-analoga.
CA1340994C (en) 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
KR930001305B1 (ko) 1989-10-19 1993-02-25 니뽕 유우시 가부시끼가이샤 당 응답형 고분자 복합체(Polymer Complexes of Sugar Response Type)
US5179189A (en) 1990-01-19 1993-01-12 Nova Pharmaceutical Corporation Fatty acid terminated polyanhydrides
DK45590D0 (hr) 1990-02-21 1990-02-21 Novo Nordisk As
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK158390D0 (da) 1990-07-02 1990-07-02 Novo Nordisk As Nye peptider
AU8091091A (en) 1990-07-26 1992-02-18 University Of Iowa Research Foundation, The Novel drug delivery systems for proteins and peptides using albumin as a carrier molecule
DK10191D0 (da) 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US5336782A (en) 1991-04-24 1994-08-09 Kuraray Co., Ltd. Long chain carboxylic acid imide ester
EP0952855B1 (en) 1991-07-03 2005-07-27 Meditech Research Limited Use of hyaluronan in gene therapy
US5268453A (en) 1991-08-08 1993-12-07 Scios Inc. Tissue-selective insulin analogs
ZA928916B (en) 1991-11-26 1994-05-18 Lilly Co Eli Tri-arginine insulins
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
WO1995007931A1 (en) 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
GB9323588D0 (en) 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
ATE264096T1 (de) 1994-03-07 2004-04-15 Nektar Therapeutics Verfahren und mittel zur verabreichung von insulin über die lunge
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
WO1996029344A1 (en) 1995-03-17 1996-09-26 Novo Nordisk A/S Insulin derivatives
US6251856B1 (en) 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
US5824638A (en) 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US20030104981A1 (en) 1995-11-03 2003-06-05 Jelena Mandic Human insulin analogues
US6451970B1 (en) 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
AU3255397A (en) 1996-07-05 1998-02-02 Novo Nordisk A/S Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides
DE69731105T2 (de) 1996-07-11 2005-11-17 Novo Nordisk A/S Verfahren zur selektiven acetylierung
ES2218622T3 (es) 1996-07-26 2004-11-16 Aventis Pharma Deutschland Gmbh Derivados de insulina con actividad de union al zinc incrementada.
US5898067A (en) 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
US6310038B1 (en) 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
CA2306877A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Insoluble insulin compositions
EP1025125B1 (en) 1997-10-24 2003-06-25 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
JP2001522793A (ja) 1997-11-12 2001-11-20 アルザ コーポレイション 経皮電気輸送送達用の緩衝処理された薬物処方物
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
JP2002518408A (ja) 1998-06-12 2002-06-25 キングス・カレツジ・ロンドン インスリン類似体
GB9814172D0 (en) 1998-06-30 1998-08-26 Andaris Ltd Formulation for inhalation
DE69936386T2 (de) 1998-08-25 2008-03-06 Advanced Inhalation Research, Inc., Cambridge Sprühgetrocknete proteinformulierungen
TW570805B (en) 1998-09-01 2004-01-11 Hoffmann La Roche Water-soluble pharmaceutical composition in an ionic complex
US7030083B2 (en) 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
DK1172114T3 (da) 1998-10-16 2005-01-24 Novo Nordisk As Stabile koncentrerede insulinpræparater til pulmonær indgivelse
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
AU2624400A (en) 1999-01-26 2000-08-07 Eli Lilly And Company Monodisperse hexameric acylated insulin analog formulations
WO2000061178A1 (en) 1999-04-13 2000-10-19 Inhale Therapeutics Systems, Inc. Pulmonary administration of dry powder formulations for treating infertility
JP2002543092A (ja) 1999-04-27 2002-12-17 イーライ・リリー・アンド・カンパニー 肺投与用インスリン結晶
US6746853B1 (en) 1999-05-19 2004-06-08 Xencor, Inc. Proteins with insulin-like activity useful in the treatment of diabetes
JP2003518917A (ja) 1999-05-19 2003-06-17 ゼンコー 糖尿病の処置に有用なインシュリン様活性を有する新規タンパク質
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1141974C (zh) 2000-06-07 2004-03-17 张昊 结肠定位释放的口服生物制剂
US6867183B2 (en) 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
YU98503A (sh) 2001-05-21 2006-05-25 Nektar Therapeutics Pulmonarno ordiniranje hemijski modifikovanog insulina
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
PT1430082E (pt) 2001-09-07 2010-01-15 Biocon Ltd Métodos de síntese de conjugados de polipéptido de insulina-oligómero, e conjugados de polipéptido de pró-insulina-oligómero e método de síntese dos mesmos
US6770625B2 (en) 2001-09-07 2004-08-03 Nobex Corporation Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
JP2005526009A (ja) 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
WO2003047493A2 (en) 2001-12-03 2003-06-12 Dor Biopharma Inc. Stabilized reverse micelle compositions and uses thereof
EP1456371A1 (en) 2001-12-05 2004-09-15 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
AU2003218635A1 (en) 2002-05-07 2003-11-11 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
ES2360182T3 (es) 2002-05-07 2011-06-01 Novo Nordisk A/S Formulaciones solubles que comprenden insulina monomérica e insulina acilada.
AU2003236521A1 (en) 2002-06-13 2003-12-31 Nobex Corporation Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
CN1165549C (zh) 2002-06-15 2004-09-08 江苏万邦生化医药股份有限公司 胰岛素的纯化方法
JP2007524592A (ja) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス 安定化された薬学的ペプチド組成物
EP1644411A2 (en) 2003-07-11 2006-04-12 Novo Nordisk A/S Stabilised insulin compositions
ES2328579T3 (es) 2003-07-25 2009-11-16 Conjuchem Biotechnologies Inc. Derivados de insulina de larga duracion y procedimientos asociados.
PL2107069T3 (pl) 2003-08-05 2013-06-28 Novo Nordisk As Nowe pochodne insuliny
AU2004264958B2 (en) 2003-08-13 2010-04-15 Biocon, Ltd Micro-particle fatty acid salt solid dosage formulations for therapeutic agents
SI2932981T1 (sl) * 2003-09-19 2021-11-30 Novo Nordisk A/S Albumin-vezavni derivati GLP-1
JP2007532096A (ja) 2003-11-14 2007-11-15 ノボ　ノルディスク　アクティーゼルスカブ アシル化されたインスリンの製造方法
EP1687019B1 (en) 2003-11-20 2017-11-22 Novo Nordisk A/S Propylene glycol-containing peptide formulations which are optimal for production and for use in injection devices
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
DE10358387A1 (de) 2003-12-13 2005-07-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulver enthaltend niedermolekulares Dextran und Verfahren zu deren Herstellung
JP4792457B2 (ja) 2004-03-26 2011-10-12 ユニヴァーシタ’デグリ ステュディ ディ パルマ 高度に呼吸に適したインスリンのマイクロ粒子
RU2006143544A (ru) 2004-05-10 2008-06-20 Нэстек Фармасьютикал Кампани Инк. (Us) Композиции и способ для облегченной чресслизистой доставки паратиреоидного гормона
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
DK2322180T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for drug delivery
AU2005311601B2 (en) 2004-12-03 2011-12-01 Rhode Island Hospital Diagnosis and treatment of Alzheimer's Disease
JP2008528549A (ja) 2005-01-27 2008-07-31 ノボ ノルディスク アクティーゼルスカブ 構造的に充分に定義された分岐ポリマーと接合されたインスリン誘導体
EP2292653B1 (en) 2005-02-02 2014-05-21 Novo Nordisk A/S Novel insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
EP1863840A1 (en) 2005-03-18 2007-12-12 Novo Nordisk A/S Pegylated single-chain insulin
WO2007006320A1 (en) 2005-07-12 2007-01-18 Sherine Hassan Abbas Helmy Drinkable oral insulin liquid and capsules
US20070086952A1 (en) 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
JP4710533B2 (ja) 2005-10-07 2011-06-29 株式会社豊田自動織機 牽引車両のドローバー装置
CA2626357A1 (en) 2005-10-20 2007-04-26 Nastech Pharmaceutical Company Inc. Intranasal administration of rapid acting insulin
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
US8343914B2 (en) 2006-01-06 2013-01-01 Case Western Reserve University Fibrillation resistant proteins
EP1991575A1 (en) 2006-02-21 2008-11-19 Novo Nordisk A/S Single-chain insulin analogues and pharmaceutical formulations thereof
ES2387955T3 (es) 2006-02-27 2012-10-04 Novo Nordisk A/S Derivados de insulina
JP2009530242A (ja) 2006-03-13 2009-08-27 ノボ・ノルデイスク・エー／エス アシル化単鎖インスリン
ES2548393T3 (es) 2006-05-09 2015-10-16 Novo Nordisk A/S Derivado de insulina
US8796205B2 (en) * 2006-05-09 2014-08-05 Novo Nordisk A/S Insulin derivative
CN101573133B (zh) 2006-07-31 2014-08-27 诺沃-诺迪斯克有限公司 Peg化延长的胰岛素
KR101729986B1 (ko) 2006-09-22 2017-04-25 노보 노르디스크 에이/에스 프로테아제 내성 인슐린 유사체
US20100120660A1 (en) 2007-04-30 2010-05-13 Per Balschmidt Highly concentrated insulin solutions and compositions
EP2164458A1 (en) 2007-06-01 2010-03-24 Novo Nordisk A/S Stable non-aqueous pharmaceutical compositions
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
JP5688969B2 (ja) 2007-07-16 2015-03-25 ノボ・ノルデイスク・エー／エス プロテアーゼに対して安定しているペグ化インスリンアナログ
KR20100053561A (ko) 2007-08-15 2010-05-20 노보 노르디스크 에이/에스 아실 및 알킬렌 글리콜 부분을 갖는 인슐린 유사체
US8962794B2 (en) 2007-08-15 2015-02-24 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
ES2543393T3 (es) * 2007-11-08 2015-08-18 Novo Nordisk A/S Derivado de insulina
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910569B1 (en) * 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
US9603904B2 (en) * 2008-10-30 2017-03-28 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
KR20130092972A (ko) * 2010-05-10 2013-08-21 노보 노르디스크 에이/에스 인슐린-아연 복합체의 제조 방법
WO2011161125A1 (en) 2010-06-23 2011-12-29 Novo Nordisk A/S Insulin derivatives containing additional disulfide bonds
CN102947331B (zh) 2010-06-23 2016-08-03 诺沃—诺迪斯克有限公司 包含额外的二硫键的胰岛素类似物
MX366314B (es) * 2010-10-27 2019-07-05 Novo Nordisk As Uso de derivados de insulina por inyecciones con intervalos variables.
EP2836508B1 (en) 2012-04-11 2016-06-29 Novo Nordisk A/S Insulin formulations

Also Published As

Publication number Publication date
BR112016007166A2 (pt) 2017-09-12
JP2017502074A (ja) 2017-01-19
HUE036702T2 (hu) 2018-07-30
PL3055325T3 (pl) 2018-06-29
EP3055325B1 (en) 2018-01-03
MX366636B (es) 2019-07-17
RU2016114098A3 (hr) 2018-05-21
RU2016114098A (ru) 2017-11-15
EP3055325A1 (en) 2016-08-17
SI3055325T1 (en) 2018-05-31
IL244507A0 (en) 2016-04-21
CN105636979B (zh) 2020-01-10
KR20160065126A (ko) 2016-06-08
DK3055325T3 (en) 2018-04-16
AU2014333979B2 (en) 2018-02-15
RU2673185C2 (ru) 2018-11-22
US20160215037A1 (en) 2016-07-28
US9896496B2 (en) 2018-02-20
JP6499184B2 (ja) 2019-04-10
SA516370893B1 (ar) 2018-08-13
AU2014333979A1 (en) 2016-03-24
PT3055325T (pt) 2018-04-06
ES2676065T3 (es) 2018-07-16
RS57004B1 (sr) 2018-05-31
CN105636979A (zh) 2016-06-01
IL244507B (en) 2018-05-31
MX2016004325A (es) 2016-07-11
WO2015052088A1 (en) 2015-04-16
CA2926701A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
HRP20180468T1 (hr) Novi derivat analoga inzulina
JP2017502074A5 (hr)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
HRP20212014T1 (hr) Spoj peptida
MX2020010300A (es) Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas.
WO2016007629A3 (en) Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations
PH12014502366B1 (en) Injectable formulation
WO2015128403A3 (en) An a22k, desb27, b29r, des b30, at epsilon position of lysine 22 acylated human insulin analogue
EA201591529A1 (ru) Лечение детского дефицита гормона роста человеческими аналогами гормона роста
CL2016000950A1 (es) Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2.
WO2014153009A3 (en) Thiosaccharide mucolytic agents
WO2014188329A3 (en) Transdermal extended dosing of pramipexole for neurological disorders
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
WO2014160155A3 (en) Implantable drug delivery compositions comprising non-polymeric sorption enhancers and methods of treatment thereof
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
JP2019529569A5 (hr)
MX2018011293A (es) Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma.
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
WO2018030881A3 (ko) 맥락막 질환의 치료를 위한 갑상선 호르몬의 용도
ES2422563A1 (es) Composición farmacéutica inyectable de ibuprofeno y arginina, su procedimiento de preparación, forma de dosificación unitaria y utilización de la misma
EA201592261A1 (ru) Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой
PH12015502560B1 (en) Use of a thiazolo pyrimidinone for the treatment of inflammatory bowel disease
PL414785A1 (pl) Kwas 3-dodecylosulfanylomasłowy do zastosowania jako lek, zwłaszcza do zapobiegania rozwojowi insulinooporności oraz kompozycja farmaceutyczna zawierająca kwas 3-dodecylosulfanylomasłowy jako substancję czynną
RU2014116836A (ru) Амид 1,2,4-триазол-3-илтиогликолевой кислоты, обладающий противовирусной активностью, или его фармацевтически приемлемые соли, фармацевтические композиции и их применение для лечения и профилактики гриппа